U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07836023) titled 'PFAS Clinical Trial' on Sept. 17.
Brief Summary: The purpose of this study is to evaluate whether treatment with cholestyramine for either one, two, three, or four months (up to 120 days), meaningfully influences per- and polyfluoroalkyl substances (PFAS) removal from the body.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Environmental Exposure
Intervention:
DRUG: Cholestyramine
Participants will be randomized to be prescribed cholestyramine therapy for one, two, three, or four months (up to 120 days in total).
Participants will be prescribed cholestyramine at a dose of 4 grams daily (one dose) for the...